リフトバレー熱ワクチン:世界の市場機会分析・予測

【英語タイトル】MarketVIEW: Rift Valley Fever vaccines - Global vaccine commercial opportunity assessment, global market forecast

VacZine Analyticsが出版した調査資料(VAZ2006001)・商品コード:VAZ2006001
・発行会社(調査会社):VacZine Analytics
・発行日:2020年7月
・ページ数:n/a
・レポート言語:英語
・レポート形式:Executive presentation (>120 slides.pdf) + 1 x MS-Excel
forecast model(s) (.xls)
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Region PriceUSD6,995 ⇒換算¥748,465見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Rift Valley Fever (RVF) is an acute zoonotic disease affecting domestic and wild ruminants and can cause moderate-to-severe illness in humans. It is caused by Rift Valley Fever Virus (RVFV), a negative single-stranded RNA arbovirus of the family Bunyaviridae (genus Phlebovirus). The main route of infection in humans is via contact with tissues and bodily fluids or consumption of raw milk from infected livestock. Mosquitos can also transmit the virus to both animals and humans. To date no human-to-human transmission has been documented.
Rift Valley Fever has mainly affected Sub-saharan Africa with major outbreaks in Kenya (1997-98), Somalia and Tanzania. More recent outbreaks have occurred in Saudi Arabia and Yemen (2000-2001). It is estimated that between 1997-2010 more than 500,000 cases of RVF occurred with over 2,000 deaths reported. A main concern is that more RVF outbreaks could occur due to the existence of competent vectors in non-endemic areas. RVF can also cause significant economic damage and famine to areas reliant on livestock rearing and food trading.

Rift Valley Fever Virus has been designated a priority pathogen by the Coalition of Epidemic Preparedness Innovations (CEPI) and the World Health Organisation. An inactivated vaccine has been developed for human use (Special Immunization Program) but its profile is not suitable (or licensed) for large scale deployment.

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>120 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a Rift Valley Fever vaccine (human) to 2040. The model (34 countries)* covers ‘at risk’ populations or identified target segments in both the public and private sector (based on latest disease understanding). A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided along with a discussion of hypothetical vaccine target product profiles (TPPs). *Some are rolled up, Photo credit: Jonas Nordberg/Unsplash

THIS PRODUCT IS A SUMMARY PRESENTATION (>120 slides, .pdf form) + 1 x FORECAST MODEL(s) (.xls)

【レポートの目次】

PRODUCT CONTENTS:
Published July 2020 (CAT No: VAMV085)
****This product is a summary presentation (.pdf), 1 x forecast models (.xls)
Contents – Summary presentation (.pdf)1
Contents
Author’s notes
Executive summary
[SECTION 1] Rift Valley Fever vaccines: key model outputs
[SECTION 2] Rift Valley Fever: disease background and epidemiology
[SECTION 3] Rift Valley Fever vaccines: R&D pipeline and competitor activity
[SECTION 4] Rift Valley Fever vaccines: modelling commercial potential
References/bibliography
About VacZine Analytics
Disclaimer
PAGES: >120 slides fully referenced/sourced. Available in .pdf form
Contents – 1 x vaccine demand models (MS Excel-based)
Worksheets = >100 interconnected



★調査レポート[リフトバレー熱ワクチン:世界の市場機会分析・予測] (コード:VAZ2006001)販売に関する免責事項を必ずご確認ください。
★調査レポート[リフトバレー熱ワクチン:世界の市場機会分析・予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆